These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26984445)

  • 1. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
    Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
    Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the potential for QTc prolongation in patients with solid tumors receiving nivolumab.
    Agrawal S; Waxman I; Lambert A; Roy A; Darbenzio R
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):635-41. PubMed ID: 26861469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
    Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
    Smith DC; Powderly J; Lee JJ; Shepard DR; Wallin J; Chaudhary A; Chao GY; Ng WT; Mitchell MI; Grau G; Kurek R; LoRusso P
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):271-80. PubMed ID: 27312733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR.
    Munasinghe WP; Mittapalli RK; Li H; Hoffman DM; Holen KD; Menon RM; Xiong H
    Cancer Chemother Pharmacol; 2017 May; 79(5):915-922. PubMed ID: 28349167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
    Munasinghe W; Stodtmann S; Tolcher A; Calvo E; Gordon M; Jalving M; de Vos-Geelen J; Medina D; Bergau D; Nuthalapati S; Hoffman D; Shepherd S; Xiong H
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):1003-1011. PubMed ID: 27709282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of enzastaurin and its metabolites on the QT interval in cancer patients.
    Welch PA; Ng WT; Darstein CL; Musib L; Lesimple T
    J Clin Pharmacol; 2016 Jan; 56(1):101-8. PubMed ID: 26096682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
    Gottfridsson C; Carlson G; Lappalainen J; Sostek M
    Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
    Wang Z; Grasela DM; Krishna G
    Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dostarlimab, an anti-programmed death-1 monoclonal antibody, does not cause QT prolongation in patients with solid tumours: A concentration-QT analysis.
    Kuchimanchi M; Dabrowski C; Lu S; Melhem M
    Br J Clin Pharmacol; 2023 Jul; 89(7):2272-2282. PubMed ID: 36823349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
    de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.
    Mondal SA; Assaf M; Liu L; O'Mara E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):251-8. PubMed ID: 26754679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
    Tan W; Giri N; Quinn S; Wilner K; Parivar K
    Invest New Drugs; 2020 Jun; 38(3):874-884. PubMed ID: 31858327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer.
    Durairaj C; Ruiz-Garcia A; Gauthier ER; Huang X; Lu DR; Hoffman JT; Finn RS; Joy AA; Ettl J; Rugo HS; Zheng J; Wilner KD; Wang DD
    Anticancer Drugs; 2018 Mar; 29(3):271-280. PubMed ID: 29360661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
    Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
    Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.